Apoptosis Induction

Apoptosis Induction refers to deliberate triggering of programmed cell death in target cells through pharmacological or biological agents activating intrinsic or extrinsic apoptotic pathways, representing a major therapeutic strategy particularly in oncology where cancer cells have acquired resistance to normal death signals.

The biopharmaceutical industry develops diverse apoptosis-inducing therapeutic modalities. BH3 mimetics like venetoclax directly activate intrinsic apoptosis blocking BCL-2 anti-apoptotic proteins, achieving approval in haematological malignancies. Death receptor agonists activate extrinsic pathway through TRAIL receptors. Proteasome inhibitors cause proteotoxic stress triggering apoptosis in plasma cells. Targeted kinase inhibitors restore apoptotic sensitivity blocking survival signals. Combination strategies sensitise cancer cells to apoptosis while activating cytotoxic killing synergistically. Predictive biomarkers identifying tumours most dependent on specific survival pathways enable personalised apoptosis-inducing strategies with improved clinical outcomes and reduced unnecessary treatment.